BOSTON & DAEJEON, South Korea–(BUSINESS WIRE)–#ADC—Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, today announced that the Company�s leadership will participate in the following virtual conferences:
About Orum Therapeutics
Orum Therapeutics is pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD2 approach to provide dual precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Companys proprietary platforms generated using the TPD2 approach includes the Antibody neoDegrader Conjugate (AnDC) platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the AnDC platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Cambridge, Massachusetts, U.S., and Daejeon, South Korea. For more information, visit www.orumrx.com.
About Orums AnDC Platform
Orums Antibody neoDegrader Conjugate (AnDC) platform is built on novel targeted protein degrader payloads combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class antibody drug conjugates (ADCs) for the treatment of cancer. The company has developed a new class of ADC payloads, called neoDegraders, to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, neoDegraders are designed to be delivered specifically to cancer cells and degrade the intracellular target protein and cause tumor cell death. The lead therapeutic programs from Orums AnDC platform are ORM-5029 for the treatment of solid tumors and ORM-6151 for the treatment of hematological cancers. Each program employs a different antibody to specifically deliver Orums lead neoDegrader to tumor cells. The company plans to file Investigational New Drug (IND) applications for ORM-5029 and ORM-6151 in 2022 and 2023, respectively.
Contacts
Corporate: Sung Joo Lee, Ph.D., Founder and CEO, Orum Therapeutics, +1-617-714-9597, contact@orumrx.com
Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., +1-858-344-8091, jessica@litldog.com
Reports First Quarter Revenues of $31.7 Million Management Reiterates 2024 Revenue Guidance of $125.0 Million…
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG)…
All amounts in US$ unless otherwise indicated VANCOUVER, British Columbia--(BUSINESS WIRE)--Capstone Copper Corp. (“Capstone” or…
Financial Highlights Q1 consolidated revenue was $49.1 million, within our guidance range of $46-51 million.…
Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®,…
DUBLIN--(BUSINESS WIRE)--The "Uzbekistan International Remittance Market Business and Investment Opportunities - Analysis by Transaction Value…